AIHTA - Publications - Search - Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer

Rothschedl, E. and Wolf, S. (2023): Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Fact Sheet Nr. 137.

[thumbnail of Fact Sheet Nr.137.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
118kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 800-910 Breast
Language:English
Series Name:Fact Sheet Nr. 137
Deposited on:24 Jul 2023 12:00
Last Modified:26 Jul 2023 10:11

Repository Staff Only: item control page